- Home
- PRME
PRME
Prime Medicine Inc.
as 07-01-2025 10:40am EST
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 191.7M | IPO Year: | 2022 |
| Target Price: | $9.38 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $6.75 | Next Earning Date: | 08-04-2025 |
| Revenue: | $3,846,000 | Revenue Growth: | 550.76% |
| Revenue Growth (this year): | 104.12% | Revenue Growth (next year): | 196.78% |
Stock Insider Trading Activity of Prime Medicine Inc. (PRME)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Liu David R. | PRME | 10% Owner | Jun 23 '25 | Buy | $2.16 | 21,000 | $45,402.00 | 20,219,945 | |
| Liu David R. | PRME | 10% Owner | Jun 16 '25 | Buy | $1.49 | 21,000 | $31,195.50 | 20,219,945 | |
| Liu David R. | PRME | 10% Owner | Jun 11 '25 | Buy | $1.60 | 21,000 | $33,589.50 | 20,219,945 | |
| Reine Allan | PRME | Chief Executive Officer | May 21 '25 | Buy | $1.18 | 125,000 | $147,150.00 | 125,000 | |
| LEE ANN L. | PRME | Chief Technical Officer | May 21 '25 | Buy | $1.13 | 100,000 | $113,000.00 | 100,000 | |
| Brudnick Richard | PRME | Chief Business Officer | May 20 '25 | Buy | $1.19 | 20,000 | $23,790.00 | 20,000 |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Prime Medicine to Participate in Upcoming Investor Conferences
Insider Monkey
a month ago
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty
MT Newswires
a month ago
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10
Zacks
a month ago
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
MT Newswires
a month ago
HC Wainwright Downgrades Prime Medicine to Neutral From Buy
MT Newswires
a month ago
JPMorgan Downgrades Prime Medicine to Neutral From Overweight
MT Newswires
a month ago
Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating
MT Newswires
a month ago
Top Midday Decliners
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.